Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (17403)	7/27/2005 2:03:47 PM
From: former_pgs	Read Replies (1) \| Respond to of 52153

Cool! The previous beta-adrenergic activation was a more blunt tool, as it obviously has multiple downstream targets. What's exciting about this CYTK data is that I'm quite convinced (through our own work) that impaired phosphate or ADP release from myosin is a primary determinant of the impaired contractility of the heart during and following a heart attack. I'm going to contact these guys and see if I can get my hands on this drug. There are a few highly selective drugs that are now available that target myosin. I'd previously considered it an undruggable target since its motor domain is relatively well conserved. I thought it likely that inhibition of cardiac myosins would trickle down to inhibiting skeletal myosins that are active in your other body muscles or even the myosins that control tone in the vasculature. This new data may change things; I'll dig to see what i can find. Please do keep us (or at least me!) posted about cytk.